Redirecting to https://www.investor.jnj.com/investor-news/news-details/2025/U-S--FDA-approves-AKEEGA-as-the-first-precision-therapy-for-BRCA2-mutated-metastatic-castration-sensitive-prostate-cancer-with-54-reduction-in-disease-progression-vs-standard-of-care/default.aspx...

Click here if your browser doesn't automatically take you to this page.